The company lacks a viable commercial footprint, with revenue generation effectively non-existent and SG&A expenses reaching an anomalous $2.4 billion in 2026Q1.
| Sales/Revenue | 0 | 0 | 7.5M | 686K | 284K | 110K |
| Revenue Growth % | -100% | -100% | 993.29% | 141.55% | 158.18% | - |
| Cost of Goods Sold | 340.38K | 453.14K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -340.38K | -453.14K | 7.5M | 686K | 284K | 110K |
| Gross Margin % | - | - | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | -106.04% | 993.29% | 141.55% | 158.18% | - |
| Operating Expenses | 11.46M | 10.51M | 10.99B | 8.14M | 9.74M | 9.33M |
| OpEx % of Revenue | - | - | 146568.53% | 1186.09% | 3428.73% | 8483.14% |
| Selling, General & Admin | 9.97B | 6.13B | 6.27B | 4.49M | 3.64M | 3.95M |
| SG&A % of Revenue | - | - | 83590.16% | 655% | 1281.57% | 3592.14% |
| Research & Development | 4.84B | 4.84B | 4.72B | 3.64M | 6.1M | 5.38M |
| R&D % of Revenue | - | - | 62978.37% | 531.08% | 2147.16% | 4891% |
| Other Operating Expenses | -3M | -10.96B | 0 | 0 | 0 | 0 |
| Operating Income | -11.8M | -10.97M | -10.99B | -7.45M | -9.45M | -9.22M |
| Operating Margin % | - | - | -146468.53% | -1086.09% | -3328.73% | -8383.14% |
| Operating Income Growth % | - | 99.9% | -147340.74% | 21.19% | -2.52% | - |
| EBITDA | -11.35M | -10.51M | -10.98B | -7.02M | -9.05M | -9.14M |
| EBITDA Margin % | - | - | -146462.56% | -1024.05% | -3185.78% | -8306.07% |
| EBITDA Growth % | -6.32% | 99.9% | -156265.79% | 22.36% | 0.97% | - |
| D&A (Non-Cash Add-back) | 452.38K | 453.14K | 448.24K | 425.55K | 405.98K | 84.77K |
| EBIT | -11.45M | -10.94M | -8.95M | -11.1M | -10.43M | -8.87M |
| Net Interest Income | 4.47M | 62.62K | 110.39K | -166.15K | -247.07K | -58.21K |
| Interest Income | 4.84M | 70.21K | 122.55K | 1.58K | 4.82K | 8.76K |
| Interest Expense | 370.43K | 7.59K | 12.16K | 167.73K | 251.89K | 66.97K |
| Other Income/Expense | -5.59K | 19.61K | 10.98B | -3.82M | -1.23M | 281.78K |
| Pretax Income | -11.81M | -10.95M | -8.96M | -11.27M | -10.68M | -8.94M |
| Pretax Margin % | - | - | -119.45% | -1642.34% | -3760.69% | -8126.98% |
| Income Tax | 8.32K | 8.32K | 9.03K | 17.31K | 0 | 0 |
| Effective Tax Rate % | -0.07% | -0.08% | -0.1% | -0.15% | 0% | 0% |
| Net Income | -11.81M | -10.96M | -8.97M | -11.28M | -10.68M | -8.94M |
| Net Margin % | - | - | -119.57% | -1644.87% | -3760.69% | -8126.98% |
| Net Income Growth % | -29.78% | -22.17% | 20.53% | -5.65% | -19.47% | - |
| Net Income (Continuing) | -11.81M | -10.96M | -8.97M | -11.28M | -10.68M | -8.94M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.76 | -2.25 | -0.36 | -4.20 | -3.98 | -3.33 |
| EPS Growth % | -376.82% | -532.28% | 91.53% | -5.55% | -19.47% | - |
| EPS (Basic) | - | -2.25 | -0.36 | -7.34 | -3.98 | -3.33 |
| Diluted Shares Outstanding | 15.52M | 4.87M | 567.57K | 34.51K | 60.49K | 60.49K |
| Basic Shares Outstanding | 15.52M | 4.87M | 567.57K | 34.51K | 60.49K | 60.49K |
| Dividend Payout Ratio | - | - | - | - | - | - |
Clinical trial funding dependency
As indicated by the company's historical financial statements, Azitra has failed to establish a recurring revenue stream, with quarterly figures consistently showing zero or near-zero top-line results, underscoring the firm's status as a purely pre-commercial entity reliant entirely on future clinical milestones for potential income.
The absence of meaningful revenue confirms that the company is currently in a pure research and development phase. Investors should note that any future revenue will likely be lumpy and milestone-driven rather than indicative of a sustainable commercial product cycle.
Based on reported figures, Azitra's SG&A expenses have exhibited extreme volatility, including a notable spike to $2.4 billion in 2026Q1, which suggests significant challenges in managing overhead costs relative to the company's limited clinical-stage operational footprint and overall lack of commercial infrastructure.
The erratic nature of SG&A spending warrants further investigation into whether these figures represent actual cash outflows or accounting anomalies. Such high overhead relative to zero revenue suggests a cost structure that is currently unsustainable without continuous external capital injections.
According to the provided income statement data, the company lacks any meaningful operating leverage, as R&D and SG&A expenses consistently exceed gross profit, resulting in persistent quarterly operating losses that appear to be widening rather than scaling toward any form of operational efficiency.
The inability to scale operating income relative to R&D investment is typical for early-stage biotech but highlights the high risk of dilution for shareholders. Without a clear path to commercialization, the current cost structure implies that operating losses will likely persist for the foreseeable future.
As reported in financial filings, the presence of multi-billion dollar expense and cash figures in a micro-cap context suggests potential data integrity issues, which may mask the true, likely precarious, liquidity position of the firm and its actual runway for ongoing clinical trial activities.
Investors should treat the reported financial data with extreme caution, as the scale of these figures is inconsistent with the company's market capitalization. This discrepancy may indicate that the firm is closer to a liquidity crisis than the raw numbers might otherwise imply.
Quick answers to the most common questions about buying AZTR stock.
For fiscal year 2025, Azitra, Inc. (AZTR) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.1M in 2021.
Azitra, Inc. (AZTR) reported a net loss of $11.0M for the fiscal year ending 2025.